Novartis1d
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
Novartis12d
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...
Novartis2d
Career Search
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis9d
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis8d
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis3d
A community of inclusion and belonging at Novartis
A workplace of inclusion, equal opportunity and respect lives at the heart of Novartis culture and is an integral part of everything we do. It is key to driving innovation and business performance as ...
Novartis14d
External funding
Novartis is reimagining medicine to improve and extend people’s lives. We provide financial support for educational, advocacy and outreach activities that help advance our goals of improving patient ...